Camurus Gestione
Criteri Gestione verificati 4/4
Camurus Il CEO è Fredrik Tiberg, nominato in Jan2003, e ha un mandato di 23.58 anni. la retribuzione annua totale è SEK 12.77M, composta da 58.8% di stipendio e 41.2% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 2.59% delle azioni della società, per un valore di SEK 959.13M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.3 anni e 4.8 anni.
Informazioni chiave
Fredrik Tiberg
Amministratore delegato
SEK 12.8m
Compenso totale
| Percentuale dello stipendio del CEO | 58.82% |
| Mandato del CEO | 23.6yrs |
| Proprietà del CEO | 2.6% |
| Durata media del management | 4.3yrs |
| Durata media del Consiglio di amministrazione | 4.8yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Aggiornamento narrativa • Jun 17
CAMX: Expanded Lilly Cardiometabolic Collaboration Will Drive Future Upside Potential
Analysts have raised their price target on Camurus from SEK610 to SEK630 as they refresh their models for fair value, factoring in updated assumptions for the discount rate, revenue growth, profit margin and a higher future P/E multiple. What's in the News for Camurus Camurus announced that Eli Lilly has exercised its option to expand their collaboration and license agreement to include amylin receptor agonists, adding another class of cardiometabolic drug candidates using Camurus' FluidCrystal technology.
Aggiornamento narrativa • Jun 03
CAMX: Expanded Cardiometabolic Partnership Will Support Further Share Price Upside
Analysts have adjusted their price target on Camurus to SEK 914 from SEK 930. This change reflects updated views on growth, profitability, a slightly higher discount rate, and expectations for a lower future P/E multiple.Articolo di analisi • May 20
The Strong Earnings Posted By Camurus (STO:CAMX) Are A Good Indication Of The Strength Of The Business
Investors were underwhelmed by the solid earnings posted by Camurus AB (publ) ( STO:CAMX ) recently. Our analysis says...Articolo di analisi • May 15
Camurus AB (publ) Just Missed EPS By 29%: Here's What Analysts Think Will Happen Next
Camurus AB (publ) ( STO:CAMX ) missed earnings with its latest quarterly results, disappointing overly-optimistic...
Aggiornamento narrativa • Apr 29
CAMX: 2026 Guidance And Earnings Outlook Will Drive Future Upside Potential
Analysts have trimmed their price target on Camurus to SEK770 from SEK814, reflecting updated views on fair value, discount rate and the balance between higher projected revenue growth and more moderate profit margins, with only a small adjustment to expected future P/E. What's in the News Camurus issued earnings guidance for 2026, setting expected revenues in a range of SEK 2.6b to SEK 2.9b (Key Developments).Aggiornamento narrativa • Apr 14
CAMX: 2026 Earnings Guidance Will Support Further Share Price Upside
Analysts have maintained their SEK 930 price target on Camurus, supported by updated forecasts that reflect slightly higher revenue growth, a marginally stronger profit margin, and a modestly lower future P/E assumption. What's in the News Camurus issued earnings guidance for 2026, with expected revenues in a range of SEK 2.6b to SEK 2.9b.Aggiornamento narrativa • Mar 31
CAMX: FDA Review Of Resubmitted NDA Will Drive Future Upside
Analysts have trimmed their 12 month price target for Camurus from SEK 660 to SEK 610, citing updated assumptions that include revised revenue growth, profit margin and future P/E expectations. What's in the News Camurus issued earnings guidance for 2026, with expected revenues of SEK 2.6b to SEK 2.9b and an operating result of SEK 0.9b to SEK 1.2b, framed against internal 2025 expectations (Key Developments).Aggiornamento narrativa • Mar 17
CAMX: 2026 Guidance And US FDA Review Will Drive Future Upside
Analysts have kept their SEK 930 price target for Camurus unchanged, citing only minor adjustments in their assumptions for revenue growth, profit margin and future P/E as the main reasons for maintaining this level. What's in the News Camurus issued earnings guidance for 2026, with expected revenues of SEK 2.6b to SEK 2.9b and an operating result of SEK 0.9b to SEK 1.2b (Corporate guidance).Aggiornamento narrativa • Mar 03
CAMX: Upcoming US And EU Launches Will Drive Future Upside Potential
Analysts have reset their price target on Camurus to SEK 930 from SEK 1,102, reflecting updated views on slightly higher forecast revenue growth, a modestly lower projected profit margin and a reduced future P/E multiple. What's in the News Camurus issued earnings guidance for 2026, expecting revenues of SEK 2.6b to SEK 2.9b and an operating result of SEK 0.9b to SEK 1.2b (Corporate guidance).Articolo di analisi • Feb 18
These Analysts Just Made A Sizeable Downgrade To Their Camurus AB (publ) (STO:CAMX) EPS Forecasts
One thing we could say about the analysts on Camurus AB (publ) ( STO:CAMX ) - they aren't optimistic, having just made...Aggiornamento narrativa • Feb 17
CAMX: FDA Review And New Partnership Will Drive Future Upside
Analysts have kept their SEK 660 price target for Camurus unchanged, with updated assumptions pointing to higher forecast revenue growth and a higher future P/E, alongside a lower projected profit margin. What's in the News Camurus issued earnings guidance for 2026, with expected revenues of SEK 2.6b to SEK 2.9b and an operating result of SEK 0.9b to SEK 1.2b, both framed relative to 2025 levels in the company communication (Corporate guidance).Aggiornamento narrativa • Feb 03
CAMX: Obesity Data And Resubmitted NDA Will Drive Future Upside Potential
Analysts have lifted their price target on Camurus from SEK 793.71 to SEK 814.17, citing updated assumptions around revenue growth, margin potential, and a lower future P/E multiple as key drivers of the change. What's in the News The U.S. FDA accepted Camurus' resubmitted New Drug Application for Oclaiz (CAM2029) for acromegaly treatment and set a PDUFA target action date of 10 June 2026, following an earlier Complete Response Letter related to a third party manufacturing facility (Key Developments).Aggiornamento narrativa • Jan 19
CAMX: Guidance Cut Will Be Offset By Pipeline Progress And New Partnership
Analysts have kept their price target for Camurus steady at SEK 660, citing updated assumptions around revenue growth, a profit margin of 72.87% and a future P/E of 12.70 as key inputs to their valuation work. What's in the News The U.S. FDA accepted Camurus' resubmitted New Drug Application for Oclaiz (CAM2029) for acromegaly, with a PDUFA target action date of 10 June 2026.Aggiornamento narrativa • Jan 05
CAMX: Revised Outlook Will Balance Guidance Cut With Pipeline And Partnership Progress
Analysts have trimmed their Camurus fair value estimate from SEK 690.00 to SEK 660.00, citing updated assumptions for the discount rate, revenue growth, profit margin and future P/E. What's in the News Camurus revised its 2025 earnings guidance, now expecting total revenue of SEK 2.3b to SEK 2.6b, compared with the previous range of SEK 2.7b to SEK 3.0b, while keeping profit before tax guidance at SEK 0.9b to SEK 1.2b (Key Developments).Aggiornamento narrativa • Dec 22
CAMX: Positive Obesity Data Will Drive Future Upside Potential
Narrative Update on Camurus Analysts have modestly raised their price target on Camurus to reflect a fair value of approximately SEK 794 per share, citing sustained strong revenue growth expectations and robust long term profit margins as key drivers of the upward revision. What's in the News Reported positive topline Phase 1b results for CAM2056, a monthly FluidCrystal semaglutide, showing dose dependent reductions in body weight, A1c, and fasting glucose that were comparable to or exceeded weekly semaglutide, with similar or better efficacy in a shorter treatment period (Key Developments).Aggiornamento narrativa • Dec 08
CAMX: Positive Obesity Data And New EU Launch Will Drive Upside
Analysts have modestly trimmed their price target on Camurus, lowering it by approximately SEK 7 to reflect slightly softer long term revenue growth and margin assumptions, partly offset by a higher expected future earnings multiple. What's in the News Positive topline Phase 1b data for monthly GLP 1 candidate CAM2056 showed dose dependent reductions in body weight, A1c, and fasting glucose that were comparable to or exceeded weekly semaglutide, with a favorable extended release profile suitable for monthly dosing (Key Developments) In the Phase 1b trial, CAM2056 10 mg achieved a mean weight loss of 9.3 percent at Day 85 versus 5.2 percent for weekly semaglutide, with statistically significant treatment difference, and similar weight reduction after 3 months as weekly semaglutide after 5 months (Key Developments) Camurus lowered its 2025 revenue guidance to SEK 2.3 billion to SEK 2.6 billion from SEK 2.7 billion to SEK 3.0 billion, while maintaining profit before tax guidance at SEK 0.9 billion to SEK 1.2 billion (Key Developments) Camurus launched Oczyesa, an octreotide subcutaneous depot for maintenance treatment of adults with acromegaly previously stabilized on somatostatin analogs, in Germany as the first EU market (Key Developments) Valuation Changes Fair Value: Trimmed slightly from SEK 800.86 to SEK 793.71, reflecting a modest downward revision in intrinsic value estimates.Articolo di analisi • Dec 08
Camurus AB (publ)'s (STO:CAMX) Intrinsic Value Is Potentially 69% Above Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, Camurus fair value estimate is kr1,022 Camurus is estimated to...Aggiornamento narrativa • Nov 24
CAMX: New European Launch And Regulatory Progress Will Drive Future Upside
Camurus's analyst price target has been slightly revised downward from SEK 801.17 to SEK 800.86. This change reflects updated assessments on growth and profitability expectations according to analysts.Articolo di analisi • Nov 19
Analysts Have Just Cut Their Camurus AB (publ) (STO:CAMX) Revenue Estimates By 11%
Market forces rained on the parade of Camurus AB (publ) ( STO:CAMX ) shareholders today, when the analysts downgraded...Articolo di analisi • Nov 09
Here's What Analysts Are Forecasting For Camurus AB (publ) (STO:CAMX) Following Its Earnings Miss
Camurus AB (publ) ( STO:CAMX ) just released its latest quarterly report and things are not looking great. It looks...Aggiornamento narrativa • Nov 07
CAMX: European Market Launch And Regulatory Wins Will Drive Profitability Higher
Analysts have lowered their price target for Camurus from SEK 832.17 to SEK 801.17. They cite modestly higher discount rates and slower projected revenue growth, although the updated outlook includes improved profit margins.Articolo di analisi • Oct 19
If EPS Growth Is Important To You, Camurus (STO:CAMX) Presents An Opportunity
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Aggiornamento narrativa • Sep 04
Global Expansion And Regulatory Approvals Will Transform Healthcare Delivery
With key metrics such as future P/E (16.49x) and net profit margin (54.67%) remaining stable, Camurus’s fair value assessment is unchanged, with the consensus analyst price target holding steady at SEK832.17. What's in the News Camurus received UK MHRA marketing authorization for Oczyesa® (octreotide subcutaneous depot) for maintenance treatment of adult acromegaly patients, following comprehensive clinical studies including two Phase 3 trials.Articolo di analisi • Jun 10
Should You Be Adding Camurus (STO:CAMX) To Your Watchlist Today?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Articolo di analisi • May 23
There May Be Underlying Issues With The Quality Of Camurus' (STO:CAMX) Earnings
Last week's profit announcement from Camurus AB (publ) ( STO:CAMX ) was underwhelming for investors, despite headline...Articolo di analisi • May 08
There's No Escaping Camurus AB (publ)'s (STO:CAMX) Muted Revenues Despite A 27% Share Price Rise
Camurus AB (publ) ( STO:CAMX ) shares have had a really impressive month, gaining 27% after a shaky period beforehand...Articolo di analisi • Mar 09
Camurus AB (publ)'s (STO:CAMX) Popularity With Investors Is Under Threat From Overpricing
There wouldn't be many who think Camurus AB (publ)'s ( STO:CAMX ) price-to-sales (or "P/S") ratio of 19.2x is worth a...
Nuova narrativa • Dec 30
Buvidal And Brixadi Expansion To Fuel Revenue Growth And Boost Profit Margins
Strong R&D pipeline and successful regulatory progress signal future revenue growth from new treatments entering various markets.Articolo di analisi • Dec 07
Camurus AB (publ)'s (STO:CAMX) P/S Is On The Mark
You may think that with a price-to-sales (or "P/S") ratio of 19x Camurus AB (publ) ( STO:CAMX ) is a stock to...Articolo di analisi • Nov 15
Investors Can Find Comfort In Camurus' (STO:CAMX) Earnings Quality
The market for Camurus AB (publ)'s ( STO:CAMX ) shares didn't move much after it posted weak earnings recently. We...Articolo di analisi • Nov 10
Camurus AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Investors in Camurus AB (publ) ( STO:CAMX ) had a good week, as its shares rose 2.5% to close at kr615 following the...Articolo di analisi • Aug 09
What Camurus AB (publ)'s (STO:CAMX) P/S Is Not Telling You
Camurus AB (publ)'s ( STO:CAMX ) price-to-sales (or "P/S") ratio of 24.3x might make it look like a sell right now...Articolo di analisi • Jul 19
Earnings Miss: Camurus AB (publ) Missed EPS By 11% And Analysts Are Revising Their Forecasts
Last week, you might have seen that Camurus AB (publ) ( STO:CAMX ) released its second-quarter result to the market...Articolo di analisi • Jul 12
We Ran A Stock Scan For Earnings Growth And Camurus (STO:CAMX) Passed With Ease
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | SEK 678m |
| Mar 31 2026 | n/a | n/a | SEK 682m |
| Dec 31 2025 | SEK 13m | SEK 8m | SEK 736m |
| Sep 30 2025 | n/a | n/a | SEK 782m |
| Jun 30 2025 | n/a | n/a | SEK 718m |
| Mar 31 2025 | n/a | n/a | SEK 548m |
| Dec 31 2024 | SEK 36m | SEK 7m | SEK 428m |
| Sep 30 2024 | n/a | n/a | SEK 266m |
| Jun 30 2024 | n/a | n/a | SEK 223m |
| Mar 31 2024 | n/a | n/a | SEK 450m |
| Dec 31 2023 | SEK 12m | n/a | SEK 431m |
| Sep 30 2023 | n/a | n/a | SEK 460m |
| Jun 30 2023 | n/a | n/a | SEK 408m |
| Mar 31 2023 | n/a | n/a | SEK 115m |
| Dec 31 2022 | SEK 10m | SEK 6m | SEK 56m |
| Sep 30 2022 | n/a | n/a | SEK 28m |
| Jun 30 2022 | n/a | n/a | -SEK 13m |
| Mar 31 2022 | n/a | n/a | -SEK 69m |
| Dec 31 2021 | SEK 10m | SEK 6m | -SEK 90m |
| Sep 30 2021 | n/a | n/a | -SEK 142m |
| Jun 30 2021 | n/a | n/a | -SEK 156m |
| Mar 31 2021 | n/a | n/a | -SEK 128m |
| Dec 31 2020 | SEK 10m | SEK 5m | -SEK 167m |
| Sep 30 2020 | n/a | n/a | -SEK 174m |
| Jun 30 2020 | n/a | n/a | -SEK 216m |
| Mar 31 2020 | n/a | n/a | -SEK 284m |
| Dec 31 2019 | SEK 8m | SEK 5m | -SEK 290m |
Compensazione vs Mercato: La retribuzione totale di Fredrik ($USD 1.34M ) è circa la media per le aziende di dimensioni simili nel mercato Swedish ($USD 1.56M ).
Compensazione vs guadagni: La retribuzione di Fredrik è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Fredrik Tiberg (63 yo)
23.6yrs
Mandato
SEK 12,773,000
Compensazione
Mr. Fredrik Tiberg has been Independent Director of Amniotics AB (publ) since 2021. He has been the Chief Executive Officer and President of Camurus AB (publ) since 2003. Mr. Tiberg serves as Chief Executi...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 23.6yrs | SEK 12.77m | 2.59% SEK 959.1m | |
| Chief Financial Officer | 1.1yrs | Nessun dato | Nessun dato | |
| Vice President of Technical Operations | 1.2yrs | Nessun dato | 0.00042% SEK 155.5k | |
| Vice President of Investor Relations | 11.6yrs | Nessun dato | Nessun dato | |
| VP of Legal & Group General Counsel | 2.6yrs | Nessun dato | Nessun dato | |
| Chief Corporate Development Officer | less than a year | Nessun dato | Nessun dato | |
| Global Head of Human Resources | 5.3yrs | Nessun dato | 0.027% SEK 10.0m | |
| Senior Vice President of R&D | no data | Nessun dato | 0.027% SEK 10.0m | |
| Chief Business Development Officer | 7.6yrs | Nessun dato | 0.068% SEK 25.0m | |
| Chief Commercial Officer | 10.2yrs | Nessun dato | 0.049% SEK 18.2m | |
| Chief Medical Officer | 3.2yrs | Nessun dato | 0.0017% SEK 621.8k | |
| President of Camurus Inc | no data | SEK 350.00k | 0.0017% SEK 621.8k |
4.3yrs
Durata media
59yo
Età media
Gestione esperta: Il team dirigenziale di CAMX è considerato esperto (durata media dell'incarico 4.3 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 24.6yrs | SEK 12.77m | 2.59% SEK 959.1m | |
| Independent Director | 5.3yrs | SEK 435.00k | Nessun dato | |
| Independent Chairman of the Board | 16.6yrs | SEK 905.00k | 0.17% SEK 63.6m | |
| Independent Director | 3.3yrs | SEK 550.00k | Nessun dato | |
| Independent Director | 1.3yrs | SEK 475.00k | Nessun dato | |
| Independent Director | 1.3yrs | SEK 450.00k | 0.0021% SEK 777.3k | |
| Director | 4.3yrs | SEK 450.00k | 0.0052% SEK 1.9m | |
| Independent Director | 6.3yrs | SEK 450.00k | 0.0071% SEK 2.6m |
4.8yrs
Durata media
62yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di CAMX sono considerati esperti (durata media dell'incarico 4.8 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/11 04:09 |
| Prezzo dell'azione a fine giornata | 2026/08/11 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Camurus AB (publ) è coperta da 12 analisti. 8 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |
| Gonzalo Artiach Castanon | Danske Bank |
| Kristofer Liljeberg-Svensson | DNB Carnegie |